NFL backs Eagles’ handling of Jalen Hurts’ blood clots — NFLPA demands a full investigation

NFL chief medical officer Allen Sills framed the Eagles’ care as careful and appropriately cautious, and league officials said they were in contact with the Eagles and the Cleveland Clinic in London throughout the evaluation that began Oct. 10. The NFL also rejected elements of media accounts about Hurts’ travel and rest before the London game, saying some reports contained misinformation.

League leaders emphasized that medical decisions are made by clinicians and that outcomes can worsen despite appropriate care. The NFL’s public posture is intended to close off calls for penalties against the Eagles — the league has said it will not punish the club over this case.

The union’s demand reflects different priorities: players want transparent records and independent review whenever a club’s medical decisions correlate with a serious, avoidable health escalation. The NFLPA has asked for more detail about who knew what and when — particularly around travel and clearance for the London game — arguing the public account leaves gaps.

That divergence — league confidence versus union suspicion — is less about bad medicine than about governance: who gets to review decisions, what records are shared, and how to ensure duties to player health are visibly prioritized over football imperatives.

Short term, the Eagles must replace an elite, injured starter and recalibrate their season plan. Longer term, this episode is likely to trigger internal or independent reviews and possible changes to how medical clearances are documented for international travel and high‑stakes games.

Expect three concrete outcomes: sharper public guidance on medical reporting for international games, more formalized pathways for NFLPA access to medical records in serious cases, and renewed scrutiny of team transparency when a player’s condition evolves rapidly after a clearance decision.